UBS Reiterates $235 Price Target on Nvidia

1 min read Reproduced verbatim
Rating
Buy
Unchanged
Target
$235
Outcome
Reached
on May 14, 2026

UBS’s latest target on NVIDIA is now $300 (Oct 9, 2026); the median of 28 firms is $315. UBS has reached 81% of its year-old targets (54 scored).

UBS and NVIDIA logos

What the analyst said

UBS analyst Timothy Arcuri reiterated on January 6, 2026, a ‘Buy’ rating and $235 price target on Nvidia.

“NVDA hosted a keynote followed by a Q&A for analysts, and we had a number of discussions with management.

Overall, we reiterate our bullish view on NVDA as we expect stock price to be driven by upwards EPS revisions for C26 and C27.

At the event, NVDA emphasized very strong demand and highlighted early stages of agentic AI and physical AI starting to contribute this year.

It more explicitly discussed Vera Rubin (now in full production and expected to ramp on track in 2H26) which is more typically launched at GTC in March.

The system-level innovation at each of the six key chips in the rack results in ~3.5x performance improvements on peak workloads.

The platform is also designed to be more modular, which should help yield/cycle time and bolster gross margin.

On the Groq deal, NVDA highlighted the on-chip memory opening some new markets where low-latency is critically important (we think of high-frequency trading), but NVDA still expects Rubin to be ~90% of compute deployed – to some degree confirming our view that Groq’s superior compiler may be the crown jewel that is truly the centerpiece of the deal.

This compiler could help to structure the data in a more predictable format and potentially allow NVDA to drive additional hardware acceleration across the entire GPU portfolio as competing hardware has begun to, in some cases, close the performance gap.

Net, we maintain our ests but still very much see an upward bias to C2026 and C2027 numbers with faster cycle times and Rubin ramp and potential resumption of China shipments (which we have previously estimated as $8-10B/Q of additional total revenue potential).

We reiterate our Buy rating and $235 PT.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Where the price stands

NVDA trades at $169. The 28 analysts who set a target in the last 3 months range from $250 to $515, with a median of $315. This $235 target is 25% below the median, the lowest on the Street.

Since the note NVDA has moved −10% (from $188). 12-month window: day 308 of 365, closes on January 6, 2027.

Track record

This call✓ Target reached on May 14, 2026, 4 months after the note. Same target as this firm’s December 29, 2025 note, so it is scored there.

Firm track recordUBS: 81% of its 54 targets at least a year old were reached within 12 months (#9 of 26 firms); on NVIDIA, 6 of 6. Accuracy ranking →

UBS on NVIDIA

UBS price targets on NVIDIA

8 calls from October 10, 2025 to February 26, 2026. The target went from $205 to $245 (+20%). The rating stayed Buy.

UBS targetNVDA share price
  1. February 26, 2026Target raised from $235 (+4%)Buy$245
  2. February 10, 2026Kept the $235 targetBuy$235
  3. January 6, 2026 This noteKept the $235 targetBuy$235
  4. December 29, 2025Kept the $235 targetBuy$235
  5. December 9, 2025Kept the $235 targetBuy$235
  6. November 20, 2025Kept the $235 targetBuy$235
  7. October 29, 2025Target raised from $205 (+15%)Buy$235
  8. October 10, 2025Earliest call shownBuy$205
Share
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.